UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 8, 2016

CV SCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-54677**	**80-0944970**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2688 South Rainbow Boulevard, Suite B
Las Vegas, Nevada 89146
(Address of principal executive offices, Zip Code)

(866) 290-2157
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-(c))

Item 7.01 Regulation FD Disclosure

On June 8, 2016, CV Sciences, Inc. (the "Company") presented materials titled *Drug Development Program and Overview* (the "Materials") at the LDMicro Invitational Conference held in Bel Air, California (the "Conference"). Some of the information in the Materials and disclosed at the Conference has not previously been disclosed publicly and as a result the Materials are furnished as Exhibit 99.1 hereto. Exhibit 99.1 is incorporated herein solely for purposes of this Item 7.01 disclosure.

Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements.

As previously disclosed in that certain Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on January 4, 2016, on January 4, 2016, the Company filed a Certificate of Amendment of Certificate of Incorporation reflecting its corporate name change to "CV Sciences,Inc.", effective January 5, 2016. In connection with the corporate name change, on June 8, 2016, the Company announced that the Financial Industry Regulatory Authority (FINRA) had approved a change in the trading symbol for the Company's common stock to "CVSI". The Company's common stock formerly traded under the symbol "CANV". A copy of the press release issued by the company in connection with the symbol change is attached hereto as Exhibit 99.2 and incorporated by reference herein.

The information set forth under Item 7.01 of this Current Report on Form 8-K ("Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1	Drug Development Program and Overview Presentation, dated June 8, 2016.
99.2	Press Release of CV Sciences, Inc., dated June 8, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 8, 2016

CV SCIENCES, INC.

By: /s/ Michael Mona, Jr.
Michael Mona, Jr.
President and Chief Executive Officer

Exhibit 99.1


CV SCIENCES™
A LIFE SCIENCE COMPANY
Drug Development Program Overview
LDMicro Invitational Conference
June 8, 2016

Safe Harbor and Disclaimer

Safe Harbor: This presentation may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks and uncertainties.

This Overview does not constitute an offer to sell or a solicitation of an offer to buy any securities of CV Sciences, Inc. The company is not soliciting any investment from this presentation or event attendees. Offers to sell or solicitations of offers to buy securities of the company will be made pursuant to the registration requirements of the Securities Act of 1933, or regulations of the Securities and Exchange Commission, and under relevant state securities laws; or in accordance with lawful exemptions from registration requirements under applicable federal and state securities laws and regulations.

Disclaimer: Mr. Jonnie R. Williams Sr., is the named inventor of the CV Sciences Inc. ("CVSI") clinical drug candidate. Additionally, Mr. Williams is the named inventor of numerous patents and patent applications including many relating to tobacco. Mr. Williams has had significant experience in the tobacco industry and is a pioneer in the reduction of tobacco-specific nitrosamines. As a matter of disclaimer, Mr. Williams currently serves as a part-time paid consultant advising CVSI on an as-requested basis in connection with its Cannabidiol ("CBD") drug development program. Mr. Williams is an independent contractor and does not serve as an employee, agent or member of CVSI management. Mr. Williams was a founder and senior officer of CanX, Inc., which CVSI acquired on December 30, 2015.

CV Sciences Inc. is a leader in marketed Cannabidiol[(a)] (CBD) products:

- Developing CBD based potential FDA approved drugs.
- Manufacturing and marketing branded consumer products.

(a) Cannabidiol (or CBD) is a compound derived from Cannabis that is reported to potentially have health benefits. ClinicalTrials.gov currently lists 100 studies utilizing CBD or other cannabidnoids.[1]

Overview of CBD Drug Development Program

In December 2015, CV Sciences acquired CanX Inc., a Pre-Clinical drug development company focusing on significant unmet medical needs.

- Initial Drug Candidate - (CVSI-007) chewing gum combines CBD and Nicotine- Patent Pending.
- Proposed Claims - To support cessation of smokeless tobacco use/addiction.
- Target Market - Smokeless tobacco market consisting of approximate $5.3 billion in annual sales to approximately 9 million consumers (US Retail).[2]
- Proposed FDA Regulatory Pathway - 505b-2.

Drug Development Program - Unmet Need

NO drug is FDA approved to support cessation of smokeless tobacco use and addiction.

Urgent Unmet Medical Need:

- Smokeless tobacco is carcinogenic (risk of esophageal, oral and pancreatic cancers).[3]
- Smokeless tobacco is strongly addictive.
- Smokeless tobacco is an epidemic as recognized by Surgeon General.
- Serious impact on youth: 5.8% of white males 12-17 years of age reported use of smokeless tobacco.[4]
- Approximately 250,000 deaths world wide each year attributed to smokeless tobacco use.[5]

Smokeless Tobacco Market

- Approximately $5.3 billion annual US retail sales of smokeless tobacco products.[6]
- Approximately 1.3 billion units of smokeless tobacco products sold annually in US.[6]
- Approximately 9 million Americans use smokeless tobacco with enormous and growing worldwide use.[7]
- Approximately 32 percent of rural, white males 12-17 years of age are either experimenting with, or at-risk for, using smokeless tobacco.[8]
- Smokeless tobacco is one of the most addictive and potent ways of consuming tobacco (holding an average-size dip in the mouth for just 30 minutes can deliver as much nicotine as smoking three cigarettes).[9]

Drug Development Program: Tobacco Use Trends



Sources: Euromonitor International [10]
National Survey on Drug Use and Health
Centers for Disease Control and Prevention

Three Requirements for successfully treating nicotine addiction



Anti Depressant Monoamine Oxidase ("MAO") Inhibitor Inhibition[11]

Drug Development Program: Initial Drug Candidate

The initial drug candidate (CVSI-007) is a chewing gum containing Nicotine and CBD to support cessation of smokeless tobacco use and addiction.

How CVSI-007 satisfies three requirements of Smokeless cessation:

1. **CBD:** to inhibit MAO and provide anti-depressant effect to replace tobacco alkaloids in pre-clinical trials.[11]
2. **Nicotine:** to address nicotine addiction and cravings.
3. **Chewing Gum:** to provide oral stimulation.

FDA Approved Nicotine Drugs to Treat Smoking Addiction

To date, the FDA has approved numerous nicotine replacement therapy drugs (NRTs) that contain nicotine as the active ingredient including chewing gum NRT's:

Nicorette	Nicotine Gum Mouth Spray Nicotine Lozenge Oral Spray
Equate	Nicotine Gum Nicotine Lozenge
Habitrol	Nicotine Gum Nicotine Lozenge
Good Sense	Nicotine Gum Nicotine Lozenge
Nicoderm	Nicotine Patch
Nicotrol	Nicotine Inhaler Nicotine Gum
Commit	Nicotine Lozenge

Proprietary In-Vitro Assay Demonstrates CBD as Antidepressant and MAO inhibition



Status of Drug Development Program

Milestones	Status
Design of initial drug candidate	Complete
Formulation and production of proprietary CGMP synthetic CBD	Complete
In-vitro Assay of CBD as a MAO inhibitor	Complete
Finalization of internal Drug Development Program	Complete
Establisment of Drug Development Team	Complete
Selection of Contract manufacturer for Drug Candidate	In Progress
Filing of initial Patent (provisional)	Complete
Pre-clinical Animal study: Safety	In Progress
Preparation for pre-IND Meeting	On Going
Preparation for filing of IND	On Going

Current regulatory environment for CBD as an FDA approved drug:

- FDA Phase 3 human clinical trials of CBD are ongoing.
- GW Pharma is seeking FDA approval for a CBD based drug based on a completed Phase 3 clinical trial.[12]
- FDA approval for a CBD drug has received encouragement from the White House and the U.S. Senate (International Caucus on Narcotics Control).[13]

CV Sciences has assembled a qualified and experienced team to lead its drug development program.

Chief Medical Officer - Dr. Chris Chapman - Dr. Chapman serves as Chairman and Chief Executive Officer of Chapman Pharmaceutical Consulting, Inc., which provides expert medical consultation on the development and management of domestic and global product development programs for biotech, pharmaceutical, and medical device products. He served as Senior Director of Medical Affairs with Quintiles/BRI, the largest contract research organization in the U.S., from 1995 until 2000. In that capacity, Dr. Chapman had oversight responsibility for the support of new drug applications, clinical studies, and device submissions to the FDA for approval. From 1992 until 1994, Dr. Chapman was Medical Director at Regeneron Pharmaceuticals. He currently serves as Chairman of the Chapman Pharmaceutical Health Foundation. Dr. Chapman is a graduate of the Georgetown University School of Medicine in Washington, D.C.

Clinical and Regulatory Advisor - Ms. Shelly Goodman - Ms. Goodman is the CEO of The FourCe LLC and is the Head of Global Drug Safety and Pharmacovigilance for Portola Pharmaceuticals, Inc. She was previously Head of Global Drug Safety for both Cerexa Pharmaceuticals and Chiron Pharmaceuticals and has been a lead consultant to biotech, pharmaceutical and device companies for many years in project management, infrastructure, compliance and product development. She has designed and managed clinical development projects, created adverse event and labeling programs, prepared companies for successful pre-approval inspections, and has launched several products. She has worked in large hospitals, as well as startup through large global corporations, CRO's, academic institutions and for the FDA.

Intellectual Property

- Proprietary cGMP formulation of Synthetic CBD for use in clinical trials.
- Initial patent application (provisional) filed.
- Banner and Wittcoff Ltd., Washington D.C. - patent counsel.

Financial Metrics

Shares Outstanding	52M
Public Float	36M
Shareholders Equity *(12/31/15)*	$23.3M
FY 2015 Revenue	$11.5M
FY 2015 Adjusted EBITDA[a]	($2.3M)
Market Cap *(6/3/16)*	$22.2 M
Market: OTCQB[b]	CVSI

a) Adjusted EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization further adjusted to exclude certain non-cash expenses and other adjustments such as stock based compensation.

b) The symbol "CVSI" became effective June 8, 2016, changed from the previous symbol of CANV.

References:

1. ClinicalTrials.gov, a service of the U.S. National Institutes of Health lists over 100 different studies utilizing Cannabidiol https://clinicaltrials.gov/ct2/results?term=cannabidiol&Search=Search
2. Statista, "Statistics and facts on smokeless tobacco in the U.S.", http://www.statista.com/topics/2500/smokeless-tobacco-in-the-united-states/
3. NIH National Cancer Institute, "Smokeless Tobacco and Cancer" http://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/smokeless-fact-sheet#q3 references the primary source International Agency for Research on Cancer. Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamines. Lyon, France: World Health Organization International Agency for Research on Cancer; 2007. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Volume 89. https://monographs.iarc.fr/ENG/Monographs/vol89/mono89.pdf
4. 50 Years of Progress: A Report of the Surgeon General, 2014. Chapter 13, page 730. http://www.surgeongeneral.gov/library/reports/50-years-of-progress/sgr50-chap-13.pdf
5. Dr. Mercola, "Smokeless Tobacco Kills More Than 250,000 Yearly, Worldwide" September 23, 2015 http://articles.mercola.com/sites/articles/archive/2015/09/23/smokeless-tobacco.aspx
6. Statista, "Statistics and facts on smokeless tobacco in the U.S.", http://www.statista.com/topics/2500/smokeless-tobacco-in-the-united-states/
7. National Cancer Institute Centers for Disease Control and Prevention U.S. Department of Health and Human Services, "Smokeless Tobacco and Public Health", p.439. http://cancercontrol.cancer.gov/brp/tcrb/global-perspective/Chapter_15_SmokelessTobaccoAndPublicHealth.pdf
8. The U.S. Food and Drug Administration, and agency of The U.S. Department of Health and Human Services, "FDA launches first ad campaign focused on dangers of smokeless tobacco among rural teens" https://www.morningstar.com/news/pr-news-wire/PRNews_20160419DC75264/fda-launches-first-ad-campaign-focused-on-dangers-of-smokeless-tobacco-among-rural-teens.print.html
9. NIH Medline Plus, a publication of the National Institutes of Health and the Friends of the National Library of Medicine, "Secondhand Smoke/"Light" Tobacco/ Smokeless Tobacco" https://www.nlm.nih.gov/medlineplus/magazine/issues/winter11/articles/winter11pg7.html
10. Adapted from "Smokeless Products Are Tough Test for Reynolds", The Wall Street Journal, March 26, 2010 http://www.wsj.com/articles/SB10001424052748703523204575129633103406778 Source: Euromonitor International 2009 data forecasts
11. Monoamine oxidases and tobacco smoking, Ivan Berlin and Robert M. Anthenelli, International Journal of Neuropsychopharmacology (2001), 4, 33–42 http://ijnp.oxfordjournals.org/content/ijnp/4/1/33.full.pdf
12. GW Pharmaceuticals, http://www.gwpharm.com/product-pipeline.aspx
13. http://www.feinstein.senate.gov/public/index.cfm/files/serve/?File_id=81b53476-64a3-4088-9bae-254a84b95ddb
U.S. Senate Caucus on International Narcotics Control, 112th Congress, 2nd Session, June 2012, "Reducing the U.S. Demand for Illegal Drugs", page 15. The White House, Office of National Drug Control Policy, "Answers to Frequently Asked Questions about Marijuana," https://www.whitehouse.gov/ondcp/frequently-asked-questions-and-facts-about-marijuana#opposed

Contact

Joseph Dowling, CFO
Tel: 866-290-2157
joseph.dowling@cvsciences.com

2688 S. Rainbow Boulevard, Suite B
Las Vegas, NV 89146

cvsciences.com

Exhibit 99.2

CV Sciences, Inc. Announces Stock Ticker Change to CVSI

Las Vegas, Nevada, June 8, 2016 – CV Sciences, Inc. (the "Company" or "CV Sciences") today announced that the Financial Industry Regulatory Authority (FINRA) has approved a change of the trading symbol of the Company's common stock. Effective today, the Company's shares of common stock will commence trading on the OTC Bulletin Board under the trading symbol "CVSI" (OTCBB:CVSI). The previous trading symbol was "CANV" (OTCBB:CANV).

About CV Sciences, Inc.

CV Sciences (OTCBB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic cannabidiol ("CBD"); and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.